ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

On-and-off fasting helps fight obesity, study finds

Can Pomegranates Slow Aging?

Calorie restriction promotes longevity through effects on mitochondrial network

Eat Your Prunes

Discover Why Ashwagandha Can Be Used for Stress and Anxiety

Lower magnesium levels linked with increased mortality risk during up to 40 years of follow-up

A spoonful of oil: Fats and oils help to unlock full nutritional benefits of veggies, study suggests

Higher resveratrol dose linked to lower glucose levels in type 2 diabetics

How Can You Benefit From Vitamin B12?

Drug can dramatically reduce weight of people with obesity

 
Print Page
Email Article

Milnacipran Clinical Study Demonstrates Effective Treatment of Fibromyalgia Pain is Distinct from Treatment of Mood

  [ 272 votes ]   [ Discuss This Article ]
www.ProHealth.com • December 17, 2003


Cypress Bioscience Inc. Announces Milnacipran Clinical Study Results Demonstrating That Effective Treatment of Fibromylagia-Related Pain is Distinct from the Treatment of Mood


SAN DIEGO--(BUSINESS WIRE)--Dec. 11, 2003--Cypress Bioscience Inc. (NASDAQ:CYPB) announced data from its Phase II Fibromyalgia Syndrome (FMS) study demonstrating that treatment with milnacipran was equally effective in reducing pain for both depressed and non-depressed patients. However, the response rate in patients treated with placebo was considerably lower in non-depressed patients than in those patients who met criteria for major depression at the time of entry into the trial.

These data indicate that the therapeutic benefits of milnacipran observed in the study are a result of its analgesic (pain elimination) properties, rather than secondary to its ability to improve mood. Milnacipran is currently being evaluated in a Phase III program for the treatment of FMS, a complex widespread pain syndrome that affects an estimated 5 million to 11 million Americans.

Milnacipran is a novel dual-acting agent that acts on two key neurotransmitters in the human body, norepinephrine and serotonin, which are involved with the central modulation and processing of chronic pain. Previously announced data from the Phase II study provides evidence that milnacipran may be an effective treatment for the pain and other symptoms associated with FMS such as fatigue, sleep disturbances, and depression.

Milnacipran is approved for non-pain indications in 22 countries, and has a well-established safety profile from its use by over 2,000,000 patients during more than six years of commercial availability in Europe, South America, and Asia.

"The patients in the Phase II study who were treated with milnacipran exhibited superior pain relief compared to the placebo-treated patients," noted Jay D. Kranzler, M.D., Ph.D., chairman of the board and chief executive officer of Cypress. "The fact that milnacipran worked equally well for both non-depressed and depressed patients, whereas the non-depressed patients had a lower placebo response rate than the depressed group, is important to our understanding of FMS.

It suggests that the pain experienced by these patients is not directly related to their mood. The effective treatment of FMS-related pain is therefore distinct from the treatment of the patients' depression."

The Phase II study was a 12-week, randomized, double-blind, placebo-controlled trial that enrolled 125 patients at several medical centers in the United States. Participants used an electronic diary to record pain, fatigue, sleep, and quality of life information frequently, on an out-patient basis. The patients' self-reporting of pain via the electronic diary was supplemented with traditional pain and quality of life inventories during monthly clinic visits. The analgesic effect of milnacipran appeared to be independent of the patients' depression status at baseline, as indicated by the similarity of pain scores between depressed and non-depressed patients.

There is no U.S. Food and Drug Administration (FDA) approved product for treating FMS, which affects 2-4% of the U.S. population, and is the second most commonly diagnosed condition in rheumatology clinics in the United States after osteoarthritis. Cypress' current clinical program constitutes the first Phase III studies ever conducted in the U.S. to assess a potential treatment for these patients. The company worked closely with FDA to agree upon a Phase III program that Cypress and the FDA mutually believe will be acceptable to support a New Drug Application for a Fibromyalgia indication.

About Cypress Bioscience Inc.

Cypress is committed to be the innovator and commercial leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other related chronic pain and central nervous system disorders. In August 2001, Cypress licensed from Pierre Fabre Medicament its first product for clinical development, milnacipran. In May 2003, Cypress restated its license agreement with Pierre Fabre. The restated license agreement provides Cypress with an exclusive license to develop and sell any products with the compound milnacipran as an active ingredient for any indication in the United States and Canada. Milnacipran, the first of a new class of agents known as NSRIs, or Norepinephrine Serotonin Reuptake Inhibitors, shares a pharmacological profile with the tricyclic antidepressants (TCAs), considered the most effective drugs for treatment of FMS, while appearing to lack the side effects associated with the latter. In October 2003, Cypress began initiating its Phase III clinical trials for the use of milnacipran as a potential treatment for FMS.
For more information about Cypress, visit the company's Web site at www.cypressbio.com.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Optimized Curcumin Longvida® Ultra EPA  - Fish Oil


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value Olea25 Olive Hydroxytyrosol Hits Astonishing 68,000+ ORAC Antioxidant Value
Safely Burn Away Body Fat Safely Burn Away Body Fat
Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue
Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients Cell-Charging Compound Gives Steady Energy to Fibromyalgia & Chronic Fatigue Patients
When a Negative is Positive - Goodnighties Recovery Sleepwear When a Negative is Positive - Goodnighties Recovery Sleepwear

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map